{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T12:27:29Z","timestamp":1783686449954,"version":"3.55.0"},"reference-count":29,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2006,1,20]],"date-time":"2006-01-20T00:00:00Z","timestamp":1137715200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2006,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Aim\u2002<\/jats:bold> To report on quality of life (QoL) and health\u2010related quality of life (HRQL) impacts of pimecrolimus (Elidel\u00ae, Novartis A.G., Basel, Switzerland, SDZ ASM 981) 1% cream in the long\u2010term treatment of paediatric atopic dermatitis.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> QoL and HRQL data are presented from two 12\u2010month international clinical trials evaluating the efficacy and safety of pimecrolimus 1% cream. Both trials were randomized and double blinded and compared two treatment strategies, one involving the use of emollients, pimecrolimus and topical corticosteroids, the other is \u2018usual care\u2019 (emollients plus topical corticosteroids) with a vehicle cream to maintain study blinding. The first trial (the infant trial) involved patients between ages 3\u00a0months and 2\u00a0years, whereas the children trial included patients aged 2\u201317\u00a0years. In both trials, QoL of the affected child's parent was evaluated with the parent's index of quality of life in atopic dermatitis (PIQoL\u2010AD). HRQL was assessed in the children trial only with the children's dermatology life quality index (CDLQI). QoL and HRQL assessments were conducted at baseline, 6\u00a0weeks, 6\u00a0months and 12\u00a0months.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Generalized linear modelling of PIQoL\u2010AD scores at each post\u2010baseline visit showed a greater impact on parent's QoL for pimecrolimus compared with control at all time\u2010points in both trials. HRQL scores showed a greater improvement from baseline for children in the pimecrolimus group compared with those in the control group at all time\u2010points.<\/jats:p><jats:p><jats:bold>Conclusions\u2002\u2002<\/jats:bold> The results show a beneficial impact of pimecrolimus on parents\u2019 QoL in paediatric atopic dermatitis, confirming findings from earlier shorter term trials. There was also a clear benefit to the HRQL of the children treated.<\/jats:p>","DOI":"10.1111\/j.1468-3083.2006.01383.x","type":"journal-article","created":{"date-parts":[[2006,1,20]],"date-time":"2006-01-20T15:49:33Z","timestamp":1137772173000},"page":"248-254","source":"Crossref","is-referenced-by-count":29,"title":["Treatment of paediatric atopic dermatitis with pimecrolimus (Elidel\u00ae, SDZ ASM 981): impact on quality of life and health\u2010related quality of life"],"prefix":"10.1111","volume":"20","author":[{"given":"SP","family":"McKenna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Whalley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"de Prost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Staab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Huels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CF","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"van Assche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,1,27]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"225","article-title":"Topical steroid treatment in infants, children, and adolescents","volume":"9","author":"Hepburn D","year":"1994","journal-title":"Adv Dermatol"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1177\/000992280003900101"},{"key":"e_1_2_6_4_2","first-page":"1130","article-title":"Potential hazards of topical steroids therapy","volume":"137","author":"Stoppolino G","year":"1983","journal-title":"Am J Dis Child"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2000.03473.x"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1159\/000018495"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.134.7.805"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.122187"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2002.126500"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.110.6.1133"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2001.04076.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.110.1.e2"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1159\/000065863"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-004-4231-z"},{"key":"e_1_2_6_15_2","first-page":"10","article-title":"The impact of childhood atopic dermatitis on the quality of life of the family","volume":"7","author":"Whalley D","year":"1999","journal-title":"J Progressive Clin Insights"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1995.tb16953.x"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.2307\/2344614"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4899-3242-6"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-005-5433-8"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.106374"},{"key":"e_1_2_6_21_2","first-page":"S58","article-title":"Which outcomes are important in schizophrenia trials?","volume":"9","author":"McKenna SP","year":"2000","journal-title":"Int J Methods Psychiatr Res"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2001.04183.x"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-6712.1998.tb00500.x"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0031-9384(00)00290-0"},{"key":"e_1_2_6_25_2","doi-asserted-by":"crossref","unstructured":"BarbierN PaulC LugerTet al.Validation of the eczema area and severity index in a population of 1550 patients with atopic dermatitis included in the pimecrolimus clinical program.Br J Dermatol2004;150:96\u2013102.","DOI":"10.1111\/j.1365-2133.2004.05696.x"},{"key":"e_1_2_6_26_2","first-page":"299","volume-title":"Quality of Life Assessment in Clinical Trials: Methods and Practice.","author":"Lydick EG","year":"1998"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2003.12251.x"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.3310\/hta4370"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.2002.01436.x"},{"key":"e_1_2_6_30_2","first-page":"294","article-title":"Social impact of atopic dermatitis","volume":"84","author":"Lapidus CS","year":"2001","journal-title":"Med Health R I"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-3083.2006.01383.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-3083.2006.01383.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T20:16:34Z","timestamp":1697055394000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-3083.2006.01383.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,27]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["10.1111\/j.1468-3083.2006.01383.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-3083.2006.01383.x","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1,27]]}}}